



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND OR MEMBER STATES OF THE EUROPEAN ECONOMIC AREA ("EEA").

## Kuros Biosciences – Stabilization Trades

Information about the stabilization in accordance with Art. 126 of the Financial Market Infrastructure Ordinance (FMIO) in registered shares of Kuros Biosciences Ltd (CH0325814116):

Trade	Size	Price	Date	Time
Buy	2'000	12.50	11.07.2017	10:00:30
Buy	157	12.40	14.07.2017	11:59:44
Buy	400	12.40	14.07.2017	12:35:57
Buy	48	12.40	14.07.2017	12:59:54
Buy	2	12.40	14.07.2017	13:02:31
Buy	19	12.40	14.07.2017	13:28:29
Buy	46	12.45	14.07.2017	13:44:16
Buy	55	12.45	14.07.2017	13:44:16
Buy	23	12.45	14.07.2017	13:44:16
Buy	26	12.50	14.07.2017	13:44:16
Buy	150	12.40	14.07.2017	13:53:07
Buy	212	12.40	14.07.2017	14:03:16
Buy	100	12.50	14.07.2017	14:15:37
Buy	326	12.40	14.07.2017	14:42:17
Buy	50	12.50	14.07.2017	15:35:25
Buy	46	12.45	14.07.2017	15:35:25
Buy	36	12.45	14.07.2017	15:35:25
Buy	19	12.45	14.07.2017	15:35:25
Buy	49	12.45	14.07.2017	15:35:25
Buy	3	12.50	14.07.2017	17:30:39
Buy	12	12.50	14.07.2017	17:30:39
Buy	21	12.50	14.07.2017	17:30:39
Buy	100	12.50	17.07.2017	12:00:02
Sell	674	12.60	28.07.2017	12:49:47
Sell	200	12.60	28.07.2017	12:49:47
Sell	20	12.60	28.07.2017	12:49:47
Sell	1'000	12.60	28.07.2017	12:49:47
Sell	606	12.60	28.07.2017	12:49:47
Sell	1'400	12.60	28.07.2017	12:51:22



**For further information, please contact:**

Kuros Biosciences Ltd  
Harry Welten, MBA  
Chief Financial Officer  
Tel: +41 79 750 15 64  
[harry.welten@kuros.ch](mailto:harry.welten@kuros.ch)

**About Kuros Biosciences Ltd**

Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit [www.kuros.ch](http://www.kuros.ch) for additional information on Kuros, its science and product pipeline.

**Forward Looking Statements**

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

**Disclaimer**

The purpose of this publication is to inform shareholders of Kuros Biosciences AG and the public. This press release does neither constitute an offer to buy or to subscribe to shares of Kuros Biosciences AG nor a prospectus within the meaning of the applicable Swiss law. Investors should make their decision to buy or to subscribe to new shares solely based on the offering and listing prospectus available free of charge at Kuros Biosciences AG, Wagistrasse 25, 8952 Schlieren / [www.kuros.ch/investors/reports-presentations](http://www.kuros.ch/investors/reports-presentations). Investors are furthermore advised to consult their bank or financial adviser.

The securities described herein are offered publicly without restrictions in Switzerland only.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE USA, IN THE UNITED KINGDOM, IN CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND OR MEMBER STATES OF THE EUROPEAN ECONOMIC AREA ("EEA") AND SHOULD NOT BE DISTRIBUTED TO U.S. PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES, THE UNITED KINGDOM, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND OR MEMBER STATES OF THE EEA AND MUST NOT BE DISTRIBUTED OR DISSEMINATED TO ONE OF THESE COUNTRIES BY PUBLICATIONS WITH A GENERAL CIRCULATION. THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. THE SECURITIES OF KUROS BIOSCIENCES AG HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933 AS AMENDED AND ARE NOT BEING OFFERED IN THE UNITED STATES OR TO U.S. PERSONS.

In relation to the United Kingdom the communication of this publication is not being made, and this publication has not been approved, by an authorized person for the purposes of Section 21 of the Financial Services and Markets Act 2000. Accordingly, this publication is not being distributed to, and must not be passed on to, the general public in the United Kingdom. Rather, the communication of this publication is



being made to, and is directed only at persons outside the United Kingdom. This publication is only available to such persons and the transaction contemplated herein will be available only to, or engaged in only with persons outside the United Kingdom, and this publication must not be acted on or relied upon by any other person.

In relation to each Member State of the EEA which has implemented the Directives 2003/71/EG dated November 4, 2003 (the "Prospectus Directive") (each a "Relevant Member State") and 2010/73/EU dated November 24, 2010, an offer to the public of shares of Kuros Biosciences AG which are the subject of the offering contemplated by this publication may not be made in that Relevant Member State. An offer to the public of shares of Kuros Biosciences AG may in particular also not be made under the provisions of Article 3 (2) of the Prospectus Directive or the respective regulations of national regulations implementing the Prospectus Directive.

The offer referred to in this press release shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.